In a planned subset analysis, patients with hormone receptor–positive breast cancer did not have a statistically significant benefit from adjuvant capecitabine; the DFS rates were 76.4% in the capecitabine group and 73.4% in the control group (HR for recurrence, second cancer, or death 0.81, 95% CI 0.55–1.17), and the OS rates were 93.4% and 94.0% (HR 0.73, 95% CI 0.38–1.40)54. Here, NR4A1 is linked to breast carcinoma.